Announcements

14DEC

Semi-Annual Reconstitution (Final) - December 2022

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Friday, December 16, 2022. All positions will be equally weighted, with weights determined as of the closing prices on Wednesday, December 14, 2022. The final changes are summarized below. LifeSci Biotechnology Clinical Trials Index (123 components as adjusted) Additions (15 stocks): ACLX, ALLK, ALT, ALVR, BHVN, CINC, COGT, DYN, FDMT, IMTX, NUVL, PLRX, SMMT, VERV, VRDN Deletions (12 stocks): ATHA, FHTX, GHRS, GOSS, IVVD, MGTX, PHAT, PRLD, RLMD, TIL, VXRT (no longer fit market cap and/or trading volume criteria) IMGN (being moved to Products Index

19OCT

Removal of Component(s) – CCXI

Effective at the market close on Wednesday, October 19, CCXI will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On August 4, 2022, ChemoCentryx, Inc. agreed to be acquired by Amgen for $52.00 per share in cash.

13JUN

Semi-Annual Reconstitution (Final) - June 2022

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index Index Semi-Annual Reconstitution (Final) The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Thursday, June 16, 2022. All positions will be equally weighted, with weights determined as of the closing prices on Tuesday, June 14, 2022. The final changes are summarized below. LifeSci Biotechnology Clinical Trials Index (121 components as adjusted) Additions (8 stocks): DSGN, EQRX, FHTX, LYEL, PCVX, PNT, SRRA, VTYX Deletions (66 stocks): ACIU, ADAP, AKBA, ALDX, ALGS, ALLK, ALVR, AMTI, ANNX, AUTL, BCAB, CGEN, CLVS, CMRX, CNTA, COGT, CRIS, CRTX, CTMX, CUE, CVM, DTIL, EPIX,

13DEC

Semi-Annual Reconstitution (Final) - December 2021

Index Semi-Annual Reconstitution (Final) December 13, 2021 The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Thursday, December 16, 2021. All positions will be equally weighted, with weights determined as of the closing prices on Tuesday, December 14, 2021. The preliminary changes, subject to modification, are summarized below. LifeSci Biotechnology Clinical Trials Index (180 components as adjusted) Additions (21 stocks): ABUS, ACET, ADGI, ATAI, AUTL, CNTA, CRBU, DAWN, DICE, ERAS, EWTX, FULC, GHRS, GRPH, IMGO, KNTE, KZR, ROIV, RXRX, TIL, VBIV Deletions (34 stocks): ADVM, ALBO, ANVS, APLT, ARDX, ATNX, AVRO, BCEL, BDTX, BOLT, CDAK, CRDF,

03NOV

Removal of Component(s) – KDMN

Effective at the market close on Thursday, November 4, KDMN will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On September 8, 2021, Kadmon Holdings, Inc. agreed to be acquired by AstraZeneca plc for $9.50 per share in cash.

15SEP

Removal of Component(s) – TBIO

Effective at the market close on Thursday, September 16, TBIO will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On August 3, 2021, Translate Bio agreed to be acquired by Sanofi for $38.00 per share in cash.

16JUL

Removal of Component(s) – ALXN

Effective at the market close on Tuesday, July 20, ALXN will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On December 12, 2020, Alexion Pharmaceuticals, Inc. agreed to be acquired by AstraZeneca plc for $60.00 per share in cash and 2.1243 ADSs (American Depositary Shares) of AstraZeneca plc.

11JUN

Semi-Annual Reconstitution (Preliminary) - June 2021

Index Semi-Annual Reconstitution (Preliminary) The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Wednesday, June 16, 2021. All positions will be equally weighted, with weights determined as of the closing prices on Monday, June 14, 2021. The preliminary changes, subject to modification, are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (51 stocks): ABCL, ACIU, ALDX, ALGS, ANVS, ATHA, AVIR, BCAB, BCYC, BOLT, CCCC, CDAK, CERE, CGEM, CLVS, CMPS, CMRX, CRIS, EPIX, EVLO, FBRX, FDMT, GMTX, GRCL, GRTS, IDYA, IMCR, KALV, KDNY, KRON, KYMR, LXRX, MGTA, MRUS, NRIX, NUVB, OLMA, PASG, PMVP,

13APR

Removal of Component(s) – FPRX

Effective at the market close on Thursdsay, April 15, 2021, FPRX will be removed from the LifeSci Biotechnology Clinical Trials Index and its values will be redistributed to the remaining index components based on their weights. On March 4, 2021, Five Prime Therapeutics agreed to be acquired by Amgen for $38.00 per share in cash.

11MAR

Removal of Component(s) – VIE

Effective at the market close on Friday March 12, VIE will be removed from the LifeSci Biotechnology Products Index and its values will be redistributed to the remaining index components based on their weights. On February 1, 2021, Viela Bio agreed to be acquired by Horizon Therapeutics plc for $53.00 per share in cash.

21JAN

Removal of Component(s) – EIDX, PRVL

Effective at the market close on Thursday January 21, EIDX and PRVL will be removed from the LifeSci Biotechnology Clinical Trials Index and their values will be redistributed to the remaining index components based on their weights. On October 5, 2020, Eidos agreed to be acquired by BridgeBio for a combination of cash and stock. On December 15, 2020, Prevail agreed to be acquired by Eli Lilly for $26.50/share in cash.

14DEC

Index Semi-Annual Reconstitution (Final) - December 2020

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Wednesday, December 16, 2020. All positions will be equally weighted, with weights determined as of the closing prices on Monday, December 14, 2020. The final changes are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (45 stocks): ADCT, AFMD, ALBO, ALVR, ALXO, AMTI, ANNX, ARCT, CDXS, CLDX, COGT, CRDF, CVAC, ETNB, FMTX, FPRX, GMDA, HGEN, IMAB, IMTX, IMVT, INBX, INO, ISEE, ITOS, KROS, LEGN, MCRB, MORF, NK, NKTX, ORIC, PGEN, PLRX, REPL, RLAY, RNA, RPTX,

09DEC

Semi-Annual Reconstitution (Preliminary) - December 2020

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Wednesday, December 16, 2020. All positions will be equally weighted, with weights determined as of the closing prices on Monday, December 14, 2020. The preliminary changes, subject to modification, are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (45 stocks): ADCT, AFMD, ALBO, ALVR, ALXO, AMTI, ANNX, ARCT, CDXS, CLDX, COGT, CRDF, CVAC, ETNB, FMTX, FPRX, GMDA, HGEN, IMAB, IMTX, IMVT, INBX, INO, ISEE, ITOS, KROS, LEGN, MCRB, MORF, NK, NKTX, ORIC, PGEN, PLRX, REPL, RLAY, RNA, RPTX, SRRK, STOK, STRO, TCRR, UROV,

11NOV

Removal of Component(s) – MYOK

Effective at the market close on Friday November 13, 2020, MYOK will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On October 5, 2020, MyoKardia, Inc. agreed to be acquired by Bristol Myers Squibb for $225.00 per share in cash.

21OCT

Removal of Component(s) – IMMU

Effective at the market close on Thursday October 22, 2020, IMMU will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On September 13, 2020, Immunomedics agreed to be acquired by Gilead Sciences for $88.00 per share in cash.